Monograph
S01EC03 - Dorzolamide |
Propably not porphyrinogenic |
PNP |
Rationale
sulfonamide mainly distributed to erythrocytes. Probably insignificant systemic load. CYP metabolised, long duration of the final elimination phase.
Chemical description
sulfonamide used in eyedrops (20 mg/mL) to reduce the intraocular pressure in glaucoma. Converted to N-desethyl dorzolamide which binds to carbanhydrase. Reaches circulation in topical application but due to effective bindnding to erytrocyte carboanhydrases the plasma levels are very low. Metabolized by CYPs 3A3/4 and 2C9/10. A final elimination phase with a half time of four months takes place after termination of treatment.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024